United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 7

Name: Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 7 comparison snapshot
Creator: Fliar BI Prism

A five-company surgical and medical instruments and apparatus cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 October 2026Not investment adviceRanked by Prism readiness

Readiness leaderInspire Medical · 46

Strongest available pathIRadimed · +128.6%

Widest latest marginIRadimed · 26.8%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1INSP · NYSE

Inspire Medical

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2007Maple Grove, Minnesota$2.05B market cap

View full Companies Radar profile

46Cautious

Snapshot price$70.78as of page date

Monthly-close return-73.7%five-year window

FY2025 revenue$0.91BInspire Medical Systems, Inc.

Net margin15.9%FY2025

P/E snapshot15.6xone ratio, not a verdict

Prism attention86.3%share across these five

Filing track recordRevenue, USD billions

+290.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 40.6%

52-week position29% through range

$38.91$147.0

News mentions11.7K

Community mentions56partial coverage

U.S.-scope patents464

Prism InsightsWhat sits behind the readiness signal
Observed risk 7/100higher means more observed risk

Earnings signal64/100
Management stability90/100
Market position3/100
Capital-event signal63/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 2 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2IVF · Nasdaq

INVO Bioscience

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2007Medford$2.3M market cap

View full Companies Radar profile

44Cautious

Snapshot price$0.90as of page date

Monthly-close return-100.0%five-year window

FY2024 revenue$0.01BINVO Fertility, Inc.

Net margin-138.6%FY2024

P/E snapshot0.0xone ratio, not a verdict

Prism attention2.8%share across these five

Filing track recordRevenue, USD billions

+532.5%

FY2020–FY2024 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2020 · CAGR 58.6%

52-week position0% through range

$0.89$84.40

News mentions377

Community mentions0partial coverage

U.S.-scope patents5

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal42/100
Management stability90/100
Market position10/100
Capital-event signal69/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 0 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3IRMD · Nasdaq

IRadimed

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2004Winter Springs, Florida$1.09B market cap

View full Companies Radar profile

44Cautious

Snapshot price$85.30as of page date

Monthly-close return+128.6%five-year window

FY2025 revenue$0.08BIRADIMED CORP

Net margin26.8%FY2025

P/E snapshot47.7xone ratio, not a verdict

Prism attention2.4%share across these five

Filing track recordRevenue, USD billions

+100.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 19.0%

52-week position41% through range

$69.47$107.9

News mentions332

Community mentions0partial coverage

U.S.-scope patents52

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal77/100
Management stability90/100
Market position10/100
Capital-event signal15/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4LMAT · Nasdaq

LeMaitre Vascular

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1983Burlington, Massachusetts$1.83B market cap

View full Companies Radar profile

44Cautious

Snapshot price$80.19as of page date

Monthly-close return+54.2%five-year window

FY2025 revenue$0.25BLEMAITRE VASCULAR INC

Net margin23.1%FY2025

P/E snapshot28.0xone ratio, not a verdict

Prism attention4.5%share across these five

Filing track recordRevenue, USD billions

+61.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.8%

52-week position5% through range

$78.22$118.0

News mentions618

Community mentions0partial coverage

U.S.-scope patents32

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal77/100
Management stability70/100
Market position20/100
Capital-event signal20/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 8 M&A involvements, 8 asset-acquisition events and 12 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5ATEC · Nasdaq

ATEC Spine

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1990San Diego, California$1.53B market cap

View full Companies Radar profile

36Cautious

Snapshot price$9.90as of page date

Monthly-close return-15.6%five-year window

FY2025 revenue$0.76BAlphatec Holdings, Inc.

Net margin-18.8%FY2025

P/E snapshot16.5xone ratio, not a verdict

Prism attention4.0%share across these five

Filing track recordRevenue, USD billions

+214.2%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 33.1%

52-week position19% through range

$6.82$23.29

News mentions549

Community mentions0partial coverage

U.S.-scope patents695

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal49/100
Management stability90/100
Market position8/100
Capital-event signal10/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

IRadimed

+128.6%

LeMaitre Vascular

+54.2%

ATEC Spine

-15.6%

Inspire Medical

-73.7%

INVO Bioscience

-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Inspire Medical

$0.91B

ATEC Spine

$0.76B

LeMaitre Vascular

$0.25B

IRadimed

$0.08B

INVO Bioscience

$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

IRadimed

26.8%

LeMaitre Vascular

23.1%

Inspire Medical

15.9%

ATEC Spine

-18.8%

INVO Bioscience

-138.6%

Prism news attention

Normalized share across these five names; attention is not quality.

Inspire Medical

86.3%

LeMaitre Vascular

4.5%

ATEC Spine

4.0%

INVO Bioscience

2.8%

IRadimed

2.4%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Inspire Medical leads the conversation

It holds 86.3% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $0.91B.

Price path

IRadimed leads the available price paths

Its monthly-close return is +128.6% for the five-year window. At the other end, INVO Bioscience is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

IRadimed has the widest latest margin

Its FY2025 net margin is 26.8%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

INVO Bioscience shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 0.0x while its five-year window price return is -100.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · INSP

Inspire Medical

11,720available Prism news records

Prism top themes

Leadership & governance

101

Earnings & financial performance

Price action & investor response

Legal, arbitration & regulatory

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-19.7%1,087 latest 12m vs 1,354 prior 12m

Machine-classified coverage tone

84.4% positive+1.5 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

electronic document management 44legal document management 40document workflow systems 39stock performance 27ldct lung screening 26early-stage lung cancer detection 26biomarkers early lung cancer 26bariatric surgery sleep apnea 26

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-15–2026-08-04 · trend and themes shown through 2026-08

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

INSP

Inspire Medical

56 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 56 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

INSP

Inspire Medical

through 2026-05-04

Earnings releases 45Leadership changes 11Lawsuits 8

2026-05-04
Earnings releases
Inspire Medical Systems (NYSE:INSP – Get Free Report) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.750-1.250 for the period, compared to the consensus earnings per share estimate of 1.990. The company issued revenue guidance of $825.0 million-$875.0 million, compared to the consensus revenue estimate of $961.2 million.
2026-02-17
Lawsuits
An investor, who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP), filed a lawsuit over alleged violations of Federal Securities Laws by Inspire Medical Systems, Inc.
2026-01-13
Leadership changes
The obstructive sleep apnea company revealed Buchholz's plans and began searching for a replacement in August.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

IVF

INVO Bioscience

through 2025-03-19

Earnings releases 11M&A 6Company announcements 1Lawsuits 1

2025-03-19
Earnings releases
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INVO Bioscience $5.77 million 0.13 -$8.03 million N/A N/A
2024-10-14
M&A
INVO Bioscience (“INVO”) (NASDAQ: INVO) today announced it has closed its merger with NAYA Biosciences
2023-10-27
Lawsuits
INVO Bioscience Inc. (Nasdaq: INVO ), relating to its proposed merger with NAYA Biosciences Inc.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

IRMD

IRadimed

through 2026-02-10

Earnings releases 42M&A 5Leadership changes 2Listing / IPO 1

2026-02-10
Earnings releases
We are thrilled to report our eighteenth consecutive quarter of record revenue, achieving $22.7 million in the fourth quarter of 2025—a 17% increase year-over-year and exceeding our previously announced guidance.
2025-09-03
Leadership changes
Effective September 2, 2025, the Board has appointed Joe Kiani, Masimo founder and renowned medical technology innovator and entrepreneur, to fill the vacancy on the Board.
2025-04-01
M&A
Barclays PLC raised its stake in shares of Iradimed by 113.9% in the 3rd quarter.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LMAT

LeMaitre Vascular

through 2025-08-15

Earnings releases 12M&A 2Asset acquisitions 1Business contracts 1Listing / IPO 1

2025-08-15
Earnings releases
LeMaitre Vascular, Inc. recently reported second-quarter earnings, with sales reaching US$64.23 million and net income rising to US$13.78 million, both up from the prior year, and declared a quarterly dividend of US$0.20 per share payable in September 2025.
2025-05-02
Business contracts
Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio—including ProxiCor®, VasCure®, and Tyke®—following the conclusion of its distribution agreement with LeMaitre Vascular, Inc.
2025-02-14
Asset acquisitions
LeMaitre Vascular (Burlington, Massachusetts), a provider of peripheral vascular devices and implants, reported acquiring all the stock of Biomateriali (Milan, Italy), a privately held vascular graft manufacturer, for E1.8 million in cash, the assumption of E1.5 million to more than E2 million in liabilities.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ATEC

ATEC Spine

through 2025-02-14

Leadership changes 2

2025-02-14
Leadership changes
Trent Northcutt has been named vice president of sales for Alphatec Spine (Carlsbad, California).
2025-02-14
Leadership changes
Peter Wulff has been named CFO/vice president/treasurer of Alphatec Spine (Carlsbad, California). He served most recently as EVP/CFO of Artes Medical.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence

2019 extracted base$10.20B–$11.75B

2025 extracted forecast$11.50B–$21.52B

Implied source CAGR7.4%

increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

72,361available Prism news records

Latest 12m volume+8.3%31410 vs 28997 records

Positive classified tone64.5%+2.2 pp vs prior four quarters

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

26Q4

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

6,734

medical drama series

6,091

cannabis legalization trends & economic impact

5,343

recreational marijuana usage

4,817

in-flight medical emergency protocols

4,029

medical marijuana laws & regulatory frameworks

3,104

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 6,292marijuana legalization arguments 5,505weed decriminalization debates 5,229cannabis industry regulations 5,056legal cannabis sales 4,967non-medical cannabis consumption 4,799medical cannabis regulations 4,532state cannabis economies 4,455

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

6,734 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,666 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

uncertainty in reimbursements

6,043 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.3% news volume

The latest 12 months contain 31,410 matched records versus 28,997 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

64.5% positive · +2.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 31–38. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 October 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Inspire Medical leads the readiness ranking

Its Prism readiness score is 46/100, the highest in this five-company comparison.

Open Inspire Medical in Companies Radar

Scale and margin leadership sit with Inspire Medical and IRadimed

Inspire Medical has the largest displayed latest revenue at $0.91B; IRadimed has the widest displayed latest margin at 26.8%.

Open Inspire Medical in Companies Radar Open IRadimed in Companies Radar

Comparisons

Strongest versus weakest available price path

IRadimed is +128.6% for its five-year window; INVO Bioscience is -100.0% for its five-year window.

Open IRadimed in Companies Radar Open INVO Bioscience in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.91B for Inspire Medical to $0.01B for INVO Bioscience. Entity and filing-period labels remain visible on the company cards.

Open Inspire Medical in Companies Radar Open INVO Bioscience in Companies Radar

Anomalies

LeMaitre Vascular has the widest attention-readiness rank gap

It ranks #2 by measured news attention (4.5%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open LeMaitre Vascular in Companies Radar

INVO Bioscience shows a price-operating divergence to inspect

Its displayed filing-revenue change is +532.5% while its available monthly-close return is -100.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open INVO Bioscience in Companies Radar

Explanations

Attention measures coverage volume, not quality

Inspire Medical's 86.3% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Inspire Medical in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Inspire Medical's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 46/100 score.

Open Inspire Medical in Companies Radar

Stress-test the largest divergence before forming a view

Compare INVO Bioscience's profile with IRadimed's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open INVO Bioscience in Companies Radar Open IRadimed in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.